Scotia Capital’s Serina Therapeutics SER Stock Holding History

Scotia Capital’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-380	Closed	-$26K	–	781
2019 Q3	$26K	Buy	+380	New	+$36K	﹤0.01%	712

Other funds holding SER

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Scotia Capital's SER Position: Q4 2019 in Review

Scotia Capital sold out of Serina Therapeutics (SER) in Q4 2019, closing a stake of 380 shares — an estimated $26K sold.

Scotia Capital first reported a position in SER in Q3 2019 and held it in 1 quarter. The position peaked at $26K in Q3 2019. 51 funds tracked by Wall St. Rank hold SER as of Q4 2019.

Scotia Capital reported no remaining Serina Therapeutics position as of Q4 2019 after selling out during the quarter.
Scotia Capital sold 380 Serina Therapeutics shares in Q4 2019, an estimated $26K.
Scotia Capital first reported a position in Serina Therapeutics in Q3 2019 and held it in 1 quarter.
Scotia Capital's Serina Therapeutics position peaked at $26K in Q3 2019.
51 funds tracked by Wall St. Rank held Serina Therapeutics as of Q4 2019.

Based on Scotia Capital's 13F filing for Q4 2019, filed 13 Feb 2020.